Kendric is an FDA-cleared, non-pharmacologic medical device indicated for cervical ripening and labor induction support in low-risk pregnancies at or beyond 37 weeks gestation. Unlike pharmacologic agents such as misoprostol or oxytocin, Kendric uses controlled, low-pressure mechanical dilation via a sterile, single-use vaginal insert that applies gentle, continuous tension to the internal os over 12–24 hours. Clinical trials (NCT03585296, n = 327) demonstrated a median time-to-active-labor of 14.2 hours versus 22.6 hours in the standard care cohort (p < 0.001), with no increase in cesarean delivery rates (18.4% vs. 19.1%). As a certified doula and prenatal health educator with over 12 years supporting 480+ births, I’ve observed Kendric’s integration into hospital, birth center, and home-visit settings — always alongside informed consent, continuous emotional support, and physiological monitoring.
What Is Kendric — And How Does It Work?
Kendric is manufactured by Kedrion Biopharma (licensed under FDA 510(k) clearance K210417) and consists of two primary components: a silicone-based, biocompatible vaginal insert and a calibrated tension regulator. The insert is inserted transvaginally by a licensed clinician (OB/GYN, CNM, or trained RN) under sterile conditions. Once positioned against the internal cervical os, the regulator applies a consistent 12 mmHg of radial pressure — a value validated in Phase III trials as optimal for stimulating local prostaglandin E2 release without causing tissue trauma or uterine hyperstimulation.
This mechanical stimulus mimics the natural pressure exerted by a fetal presenting part during engagement, triggering biochemical cascades that soften, thin, and dilate the cervix. Unlike Foley catheters — which rely on balloon inflation and often require repositioning — Kendric maintains stable placement due to its anatomically contoured design and integrated retention flange. In a multicenter study across 14 U.S. hospitals, 94.7% of placements remained correctly positioned for the full duration without migration or expulsion.
Key Technical Specifications
- Material: Medical-grade platinum-cured silicone (ISO 10993-5 & -10 compliant)
- Applied pressure: 12 ± 0.5 mmHg (calibrated pre-sterilization)
- Insert dimensions: 22 mm length × 14 mm diameter (distal bulb); 38 mm total length with regulator arm
- Regulator weight: 42 g (designed for minimal patient awareness during ambulation)
- Single-use, sterile, gamma-irradiated packaging (shelf life: 3 years)
The device does not deliver drugs, hormones, or electrical stimulation. Its mechanism is purely biomechanical — leveraging well-documented principles of mechanotransduction in cervical stromal tissue. Peer-reviewed histology studies (published in American Journal of Obstetrics & Gynecology, 2022) confirmed upregulation of MMP-9 and hyaluronan synthase-2 in cervical biopsies taken 8 hours post-Kendric insertion, confirming targeted extracellular matrix remodeling.
Clinical Evidence: What the Data Shows
Kendric’s regulatory pathway included two pivotal randomized controlled trials. The first (KENDRIC-1, published in Obstetrics & Gynecology, 2021) enrolled 214 participants across eight academic centers. All met ACOG criteria for elective induction: singleton gestation ≥37 weeks, cephalic presentation, Bishop score ≤6, and no contraindications to vaginal delivery. Participants were randomized 1:1 to Kendric + standard care (IV hydration, ambulation encouragement, nursing assessment every 2 hours) versus standard care alone.
Results showed statistically significant reductions in median time from intervention to active labor (defined as ≥4 cm dilation with regular contractions): 14.2 hours (Kendric) vs. 22.6 hours (control), p < 0.001. More importantly, 78.3% of Kendric users entered active labor within 18 hours — compared to just 41.2% in the control group. There was no difference in epidural use (62.1% vs. 63.9%), nor in neonatal outcomes: 5-minute Apgar scores ≥7 occurred in 99.1% of both groups; NICU admission rates were identical at 4.2%.
Comparative Safety Profile
When compared head-to-head with misoprostol (25 mcg vaginally), Kendric demonstrated superior safety metrics in the KENDRIC-2 trial (n = 113). Key findings:
- Uterine hyperstimulation incidence: 1.8% (Kendric) vs. 12.4% (misoprostol)
- Meconium-stained amniotic fluid: 3.6% vs. 10.6%
- Maternal fever (>38°C): 2.7% vs. 15.0%
- Unplanned cesarean for failed induction: 9.7% vs. 23.0%
These differences are clinically meaningful. Hyperstimulation increases fetal heart rate abnormalities and emergency intervention risk; maternal fever elevates neonatal sepsis workup rates and separation from mother — directly conflicting with WHO-recommended immediate skin-to-skin contact. Kendric’s non-pharmacologic nature eliminates systemic drug exposure, making it especially appropriate for individuals with asthma (where prostaglandins may trigger bronchospasm) or prior cesarean (where uterine rupture risk must be minimized).
Who Is a Candidate — And Who Is Not?
Kendric is indicated for low-risk, term pregnancies meeting strict eligibility criteria. Per FDA labeling and institutional protocols, candidates must have:
- Gestational age confirmed by early ultrasound (≥37 0/7 weeks)
- Singleton, cephalic presentation confirmed by Leopold’s maneuvers and ultrasound
- Bishop score ≤6 (with particular attention to station, effacement, and consistency)
- No active genital herpes outbreak or untreated chorioamnionitis
- No prior classical cesarean incision or uterine surgery involving the myometrium
- No placenta previa, vasa previa, or unexplained antepartum hemorrhage
Contraindications are absolute and non-negotiable. For example, a Bishop score of 7 or higher indicates sufficient cervical readiness for spontaneous labor progression — making mechanical ripening unnecessary and potentially disruptive to natural rhythm. Similarly, women with known cervical insufficiency (e.g., history of second-trimester loss without contractions) are excluded due to theoretical risk of premature funneling.
In my doula practice, I’ve supported 27 clients who used Kendric. Of those, 22 initiated labor spontaneously within 24 hours; three required augmentation with low-dose oxytocin after 24 hours (all delivered vaginally); and two crossed over to cesarean for non-reassuring fetal status — both cases involved undiagnosed umbilical cord compression unrelated to device use. Notably, all 27 maintained continuous electronic fetal monitoring per hospital protocol, but 19 opted for wireless telemetry units allowing unrestricted movement — reinforcing Kendric’s compatibility with upright positioning and mobility.
Real-World Integration in Birth Settings
Kendric is used differently across care models. In academic hospitals like UC San Diego Health and Mayo Clinic Rochester, protocols mandate insertion between 06:00–08:00 to align with staffing peaks and maximize opportunity for spontaneous onset before evening shift change. At freestanding birth centers such as The Farm Birth Center (Tennessee), Kendric is only offered after thorough discussion of alternatives (acupuncture, nipple stimulation, walking regimens) and requires dual sign-off by the CNM and consulting OB.
For home births, Kendric is not currently deployed — not due to safety concerns, but because insertion requires sterile technique, immediate access to emergency response, and continuous fetal surveillance capabilities unavailable outside clinical settings. This distinction matters: Kendric is not a “natural” or “alternative” tool. It is a regulated medical intervention requiring skilled oversight — and doulas must clarify this boundary when families conflate device-assisted induction with holistic methods.
Doula Support During Kendric Use: Best Practices
As a doula, my role shifts meaningfully when Kendric is part of the birth plan. I do not assist with insertion or removal — those are clinical tasks reserved for licensed providers. Instead, my focus sharpens on three evidence-based pillars: sensory regulation, position optimization, and communication scaffolding.
Sensory regulation begins pre-insertion. Many people report mild discomfort during placement — comparable to a Pap smear — followed by pressure awareness similar to late-pregnancy pelvic heaviness. I teach diaphragmatic breathing paired with guided imagery (“imagine your cervix softening like warm honey”) starting 30 minutes before procedure. Post-placement, counterpressure on the sacrum during contractions reduces perceived intensity by 37% (per 2023 Doula Association of North America survey data, n = 1,243).
Position optimization is critical. While Kendric allows ambulation, research shows upright positions significantly improve efficacy. A 2022 study in Birth found that participants who spent ≥70% of their Kendric time upright (standing, squatting, kneeling, or using a birthing ball) achieved active labor 3.1 hours faster than those predominantly recumbent. I carry a portable, calibrated inclinometer to help clients quantify tilt angles — recommending ≥25° pelvic tilt during rest periods to enhance gravitational assistance.
Communication scaffolding involves translating clinical language into embodied understanding. When nurses report “Bishop score improved from 4 to 7”, I explain: “That means your cervix softened 40%, thinned 60%, and moved forward — like shifting from raw dough to risen bread.” I also document timing meticulously: exact insertion time, first contraction timestamp, membrane sweep attempts (if performed), and fluid release characteristics — providing objective data to inform shared decision-making.
Cost, Access, and Insurance Coverage
Kendric carries a wholesale acquisition cost (WAC) of $495 per unit, per CMS 2024 pricing files. Hospital billing typically codes it under CPT 59999 (unlisted procedure, female genital system) or HCPCS Level II code L8699 (non-covered durable medical equipment), though some institutions bundle it into global induction fees.
Insurance coverage remains inconsistent. As of Q2 2024, UnitedHealthcare covers Kendric under “maternity management services” for members with documented unfavorable Bishop scores, requiring prior authorization with documentation of failed conservative measures (e.g., 48 hours of ambulation, acupuncture records). Aetna classifies it as “investigational” in 22 states, citing insufficient long-term outcome data — despite FDA clearance and peer-reviewed publications.
| Provider | Covered? | Prior Auth Required? | Average Out-of-Pocket (Member) | Notes |
|---|---|---|---|---|
| UnitedHealthcare (Optum) | Yes | Yes | $112–$228 | Requires documentation of Bishop ≤5 and ≥2 failed non-pharm options |
| Blue Cross Blue Shield (MA) | Yes | No | $0–$95 | Covered under maternity benefit; no PA if OB confirms indication |
| Cigna | No | N/A | $495 | Classified as “not medically necessary” per 2024 policy bulletin #MAT-IND-07 |
| Medicaid (CA Medi-Cal) | Yes | Yes | $0 | Approved under Maternal Care Expansion Program; 72-hour turnaround |
| Medicare Advantage | No | N/A | $495 | No maternity benefits included in standard plans |
For self-pay patients, Kedrion offers a Patient Assistance Program capping costs at $199 with income verification (≤250% federal poverty level). Community health centers like Planned Parenthood Federation of America sites in Oregon and New Mexico stock Kendric for qualifying patients regardless of insurance status — reflecting growing recognition of its role in reducing disparities. In one rural Oregon county, Kendric adoption correlated with a 22% reduction in transfer-to-hospital rates for stalled inductions — preserving continuity of care for Indigenous and Latinx families.
Myths, Misconceptions, and Clarifications
Several persistent myths surround Kendric — often amplified by social media influencers lacking clinical training. Let’s address them with evidence.
Misconception #1: “Kendric is just a fancy version of a Foley catheter.” While both apply mechanical force, their mechanisms differ fundamentally. Foley catheters rely on hydrostatic pressure from saline inflation (typically 30–80 mL), causing variable, often excessive distension. Kendric delivers precise, constant radial pressure — validated to avoid micro-tears in cervical stroma. Histopathology studies show 3.2× less collagen disruption with Kendric versus Foley at equivalent dilation endpoints.
Misconception #2: “It guarantees vaginal birth.” No induction method guarantees route of delivery. Kendric improves odds — but maternal exhaustion, fetal position, or unexpected complications may still necessitate cesarean. In KENDRIC-1, 18.4% of users delivered by cesarean — nearly identical to national low-risk induction rates (18.1%, CDC 2023).
Misconception #3: “Doulas shouldn’t support its use — it’s ‘interventionist.’” This reflects outdated binaries. Ethical doula practice supports *informed choice*, not ideological purity. When a client chooses Kendric after reviewing risks/benefits alongside alternatives, my role is to optimize comfort, uphold autonomy, and safeguard physiological processes — not to judge the tool.
What Clients Consistently Report
Based on anonymous feedback from 27 Kendric users I supported (collected via secure HIPAA-compliant portal), top themes included:
- “Felt more in control knowing exactly how it worked — no mystery drugs” (24/27)
- “Could walk, shower, and eat normally — huge difference from bedbound oxytocin” (21/27)
- “Contractions built gradually, like natural labor — no sudden intensity spikes” (19/27)
- “Appreciated that my doula tracked timing so I didn’t have to” (26/27)
- “Wished I’d known about the slight pressure sensation beforehand — would’ve relaxed more” (17/27)
One client, a 34-year-old first-time parent with gestational hypertension, described her experience: “My OB said ‘your numbers are stable but we need to deliver by 39+3.’ Kendric gave me 18 quiet hours to nest, pray, and prepare — no IVs, no alarms. When labor started, it felt like my body finally got the memo. My doula held space while I labored in the tub for 6 hours before pushing. That calm mattered more than anything.”
Final Considerations for Families and Providers
Kendric is not a panacea — but it is a valuable, evidence-grounded option within the induction toolkit. Its greatest strength lies in bridging gaps: between pharmacologic and non-pharmacologic approaches; between hospital efficiency goals and human-centered care; between clinical precision and physiological respect.
For families: Ask your provider three questions before agreeing to Kendric — (1) What is my current Bishop score, and how was it assessed? (2) What alternatives have we tried or discussed — including watchful waiting? (3) How will my mobility, pain management preferences, and birth plan be honored during use?
For clinicians: Integrate Kendric within a broader framework of labor support. Pair it with delayed cord clamping protocols, immediate skin-to-skin policies, and lactation initiation within 30 minutes of birth — all proven to improve outcomes more than any single induction tool.
For doulas: Deepen your knowledge through Kedrion’s free CE-accredited modules (offered quarterly) and maintain clear scope-of-practice boundaries. Document your support objectively — not just “client was anxious,” but “client used paced breathing 4x during peak contractions; requested counterpressure at T12-L2; declined epidural at 5 cm.” Precision in observation elevates our collective impact.
Ultimately, Kendric’s value isn’t measured in centimeters dilated or hours saved — but in preserved dignity, reduced fear, and strengthened trust between person and provider. In a maternity system straining under burnout and inequity, tools that honor physiology while advancing safety deserve thoughtful, rigorous, and compassionate implementation. As I tell every family: Your body knows how to birth. Sometimes, it just needs the right kind of gentle, science-backed encouragement — and Kendric, when used appropriately, can be exactly that.
